Information Provided By: 
Fly News Breaks for September 17, 2015
OCRX
Sep 17, 2015 | 07:58 EDT
After Ocera began a Phase I trial of an oral version of its hepatic encephalopathy drug, JMP Securities says the oral drug could expand the company's opportunity beyond acute care, to chronic care. The firm thinks that an oral version of the drug would be very well-received by doctors. JMP reiterates a $15 price target and Outperform rating on the stock.
News For OCRX From the Last 2 Days
There are no results for your query OCRX
